ArticleGynecologic oncology reports2016
Treatment and follow-up of malignant struma ovarii: Regarding two cases.
Article in Gynecologic oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Optimal Strategies for the Surgical and Long-Term Management of Malignant Struma Ovarii.Case reports in endocrinology · 2026Article
- Recurrent malignant struma ovarii presenting as peritoneal carcinomatosis in the setting of an intact thyroid: A case report and review of the literature.Gynecologic oncology reports · 2024Article
- Review
- A case report of malignant struma ovarii with papillary thyroid carcinoma.Clinical case reports · 2024Article
- Presentation and treatment of two cases of malignant struma ovarii.BMC women's health · 2024Article
- Papillary thyroid carcinoma arising from a mature ovarian teratoma coexisting with stromal luteoma: the first case report in the literature.Journal of surgical case reports · 2023Article
- Papillary thyroid carcinoma in struma ovarii: management after surgery.BMJ case reports · 2022Article
- Giant struma ovarii with pseudo-Meigs'syndrome and raised cancer antigen-125 levels: A case report.World journal of clinical cases · 2022Article
- Malignant Clinical Course of "Proliferative" Ovarian Struma: Diagnostic Challenges and Treatment Pitfalls.Diagnostics (Basel, Switzerland) · 2022Article
- Huge follicular carcinoma originated from struma ovarii in young woman; Extremely rare case.Annals of medicine and surgery (2012) · 2021Article
- Malignant Struma Ovarii with Concurrent Thyroid Cancer: Outcomes during and after Pregnancy.European thyroid journal · 2021Article
- Struma ovarii and peritoneal strumosis during pregnancy.BMC pregnancy and childbirth · 2021Article
- Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature.Case reports in endocrinology · 2019Article
- Treatment and follow-up in an asymptomatic malignant struma ovarii: A case report.International journal of surgery case reports · 2017Article
- High dose Radioiodine Therapy Preceded by Fertility Preservation Surgery in Metastatic Malignant Struma Ovarii: A Tale of Endurance and Prudent Management.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
- The Smallest Reported Malignant Struma Ovarii: A Case Report.Case reports in oncologyArticle
- Successful Management and Long-term Survival of Malignant Struma Ovarii with Radioactive Iodine Therapy.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant struma ovarii (SO) is a rare tumor, and as a consequence, treatments and follow-up procedures are not clearly established. Presented in this study are two cases of suspicious ovarian masses, resected and corresponding to malignant SO on histopathology. Similar to thyroid cancer, we proposed complementary radioiodine therapy ((131)I) after total thyroidectomy (no malignancy was observed at this level in our two patients). Patients underwent treatment with 3.7 GBq (131)I followed by post-therapy whole-body scintigraphy, which can detect residual disease or occult metastases. Thyroid remnant ablation increases the sensitivity and specificity of follow-up testing using serum thyroglobulin levels as a tumor marker. Our two patients remained disease-free for 3 and 5 years, respectively, after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.